
ExpreS2ion Biotech Holding
28.6
SEK
-2.72 %
EXPRS2
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
ExpreS2ion is a biotechnology company focused on the development of vaccines. The company aims to contribute to healthcare by developing vaccines that support disease prevention and improve quality of life globally. ExpreS2ion utilizes its ExpreS2™ technology platform, which has been validated in Phase III clinical studies, for the development and production of vaccine components. Among its ongoing projects, ExpreS2ion is advancing ES2B-C001, a HER2-cVLP breast cancer vaccine undergoing Phase I clinical trials.
Read moreLatest research
Latest analysis report
Released: 23.12.2024
Financial calendar
Interim report Q1'25
General meeting '25
Interim report Q2'25


ExpreS2ion Biotechnologies - Presentation of Q4 2024
ExpreS2ion Biotechnologies: ExpreS2ion announces financial results for the fourth quarter of 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
ExpreS2ion Biotechnologies: ExpreS2ion to Present in Upcoming Investor and Scientific Events

Dagens aktienyheder 27/12: Ascelia Pharma og ExpreS2ion Biotech

ExpreS2ion Biotech (One-pager): Market value below cash balance

ExpreS2ion Biotech – A look back at 2024 with CEO
ExpreS2ion Biotechnologies: Publication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine
ExpreS2ion Biotechnologies: Analysguiden Publishes Research Report on ExpreS2ion Biotech with Price Target of SEK 91

Dagens aktienyheder 09/12: Danske Bank, ExpreS2ion Biotechnologies og GomSpace
ExpreS2ion Biotechnologies: Warrants of series TO 10 were exercised to approximately 69 percent and ExpreS2ion receives approximately SEK 10 million

Dagens aktienyheder 03/12: ExpreS2ion Biotechnologies og Ascelia Pharma
ExpreS2ion Biotechnologies: ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer
ExpreS2ion Biotechnologies: ExpreS2ion publishes video presentations from Biostock Life Science Summit and Analysguiden Stora Aktiedagarna
ExpreS2ion Biotechnologies: Last day of trading in warrants of series TO 10 in Expres2ion Biotech Holding AB is today, 2 December 2024
ExpreS2ion Biotechnologies: Full commitments from members of ExpreS2ion's Board and Management holding warrants of series TO 10
ExpreS2ion Biotechnologies: ExpreS2ion announces the start of the exercise period for warrants of series TO 10
ExpreS2ion Biotechnologies: ExpreS2ion to present in upcoming investor and scientific events
ExpreS2ion Biotechnologies: ExpreS2ion announces TO 10 warrant exercise price and start of exercise period
